Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 5Completed 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Infusions, Intravenous × 1 year × Clear all
NCT06505837 2025-08-28

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer(NSCLC)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Active not recruiting
395 enrolled
Thoracic

Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer

NCT05894889 2025-07-23

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Peking University

Phase 2 Active not recruiting
70 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡